The Growing Impact of Biosimilars in IBD Care (AJMC)

Biosimilars are increasingly transforming inflammatory bowel disease (IBD) care by offering cost-effective alternatives to expensive biologics with comparable safety and efficacy. A recent review in Clinical and Experimental Medicine emphasized their potential to improve access to IBD treatments globally, especially in low- and middle-income countries.The study also explores innovative drug delivery systems (DDSs) — such as nanoparticle-based therapies — which could enhance targeted treatment, reduce systemic side effects, and improve patient experience. As IBD incidence rises worldwide, these advances aim to make care more effective, affordable, and accessible.